Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients: a nested case-control study

Chao Feng Lin, Hung Yi Chiou, Ya Hui Chang, Ju Chi Liu, Yen Ni Hung, Ming Tsang Chuang, Li Nien Chien

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Purpose: Hypnotic use might cause altered inflammatory processes, which have been suggested as being related to the mechanisms of arteriovenous fistula (AVF) failure. Therefore, we examined the association between the risk of AVF failure and hypnotic use in patients receiving hemodialysis (HD). Methods: A nested case–control study was conducted using data from the National Health Insurance Research Database of Taiwan. From 34 165 HD patients, 3676 patients receiving percutaneous transluminal angioplasty or surgical thrombectomy for AVF failure were matched to 14 704 control patients according to sex, age (±1 year), and the year of initial HD therapy. The risk of AVF failure was estimated based on conditional logistic regression after adjustment for the timing of AVF creation, HD frequency, comorbidities, and prescribed medications. Hypnotic use was measured prior to the date of AVF failure of case patients and the date of pseudo-AVF failure of controls. Results: Compared with matched controls, case patients were more likely to be exposed to hypnotics 30 days or an average daily defined dose > 0.5 within 90 days before the date of AVF failure, with an adjusted odds ratio of 1.21 (95% confidence interval [CI]: 1.09–1.35, p < 0.001) and 1.36 (95%CI: 1.13–1.63, p = 0.001), respectively. Risk of AVF failure associated with hypnotic use was also observed among HD patients who were male, were younger than 65 years, had hypertension, and did not use statins. Conclusions: Hypnotic use among HD patients was associated with an increased risk of AVF failure.

原文英語
頁(從 - 到)889-897
頁數9
期刊Pharmacoepidemiology and Drug Safety
25
發行號8
DOIs
出版狀態已發佈 - 八月 1 2016

指紋

Arteriovenous Fistula
Hypnotics and Sedatives
Renal Dialysis
Case-Control Studies
Confidence Intervals
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thrombectomy
National Health Programs
Taiwan
Angioplasty
Comorbidity
Logistic Models
Odds Ratio
Databases
Hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

引用此文

Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients : a nested case-control study. / Lin, Chao Feng; Chiou, Hung Yi; Chang, Ya Hui; Liu, Ju Chi; Hung, Yen Ni; Chuang, Ming Tsang; Chien, Li Nien.

於: Pharmacoepidemiology and Drug Safety, 卷 25, 編號 8, 01.08.2016, p. 889-897.

研究成果: 雜誌貢獻文章

@article{fa5026ab3cab47db9018bb2b2ef05972,
title = "Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients: a nested case-control study",
abstract = "Purpose: Hypnotic use might cause altered inflammatory processes, which have been suggested as being related to the mechanisms of arteriovenous fistula (AVF) failure. Therefore, we examined the association between the risk of AVF failure and hypnotic use in patients receiving hemodialysis (HD). Methods: A nested case–control study was conducted using data from the National Health Insurance Research Database of Taiwan. From 34 165 HD patients, 3676 patients receiving percutaneous transluminal angioplasty or surgical thrombectomy for AVF failure were matched to 14 704 control patients according to sex, age (±1 year), and the year of initial HD therapy. The risk of AVF failure was estimated based on conditional logistic regression after adjustment for the timing of AVF creation, HD frequency, comorbidities, and prescribed medications. Hypnotic use was measured prior to the date of AVF failure of case patients and the date of pseudo-AVF failure of controls. Results: Compared with matched controls, case patients were more likely to be exposed to hypnotics 30 days or an average daily defined dose > 0.5 within 90 days before the date of AVF failure, with an adjusted odds ratio of 1.21 (95{\%} confidence interval [CI]: 1.09–1.35, p < 0.001) and 1.36 (95{\%}CI: 1.13–1.63, p = 0.001), respectively. Risk of AVF failure associated with hypnotic use was also observed among HD patients who were male, were younger than 65 years, had hypertension, and did not use statins. Conclusions: Hypnotic use among HD patients was associated with an increased risk of AVF failure.",
keywords = "arteriovenous fistula failure, hemodialysis, hypnotics, nested case–control study, pharmacoepidemiology",
author = "Lin, {Chao Feng} and Chiou, {Hung Yi} and Chang, {Ya Hui} and Liu, {Ju Chi} and Hung, {Yen Ni} and Chuang, {Ming Tsang} and Chien, {Li Nien}",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/pds.3963",
language = "English",
volume = "25",
pages = "889--897",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Risk of arteriovenous fistula failure associated with hypnotic use in hemodialysis patients

T2 - a nested case-control study

AU - Lin, Chao Feng

AU - Chiou, Hung Yi

AU - Chang, Ya Hui

AU - Liu, Ju Chi

AU - Hung, Yen Ni

AU - Chuang, Ming Tsang

AU - Chien, Li Nien

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: Hypnotic use might cause altered inflammatory processes, which have been suggested as being related to the mechanisms of arteriovenous fistula (AVF) failure. Therefore, we examined the association between the risk of AVF failure and hypnotic use in patients receiving hemodialysis (HD). Methods: A nested case–control study was conducted using data from the National Health Insurance Research Database of Taiwan. From 34 165 HD patients, 3676 patients receiving percutaneous transluminal angioplasty or surgical thrombectomy for AVF failure were matched to 14 704 control patients according to sex, age (±1 year), and the year of initial HD therapy. The risk of AVF failure was estimated based on conditional logistic regression after adjustment for the timing of AVF creation, HD frequency, comorbidities, and prescribed medications. Hypnotic use was measured prior to the date of AVF failure of case patients and the date of pseudo-AVF failure of controls. Results: Compared with matched controls, case patients were more likely to be exposed to hypnotics 30 days or an average daily defined dose > 0.5 within 90 days before the date of AVF failure, with an adjusted odds ratio of 1.21 (95% confidence interval [CI]: 1.09–1.35, p < 0.001) and 1.36 (95%CI: 1.13–1.63, p = 0.001), respectively. Risk of AVF failure associated with hypnotic use was also observed among HD patients who were male, were younger than 65 years, had hypertension, and did not use statins. Conclusions: Hypnotic use among HD patients was associated with an increased risk of AVF failure.

AB - Purpose: Hypnotic use might cause altered inflammatory processes, which have been suggested as being related to the mechanisms of arteriovenous fistula (AVF) failure. Therefore, we examined the association between the risk of AVF failure and hypnotic use in patients receiving hemodialysis (HD). Methods: A nested case–control study was conducted using data from the National Health Insurance Research Database of Taiwan. From 34 165 HD patients, 3676 patients receiving percutaneous transluminal angioplasty or surgical thrombectomy for AVF failure were matched to 14 704 control patients according to sex, age (±1 year), and the year of initial HD therapy. The risk of AVF failure was estimated based on conditional logistic regression after adjustment for the timing of AVF creation, HD frequency, comorbidities, and prescribed medications. Hypnotic use was measured prior to the date of AVF failure of case patients and the date of pseudo-AVF failure of controls. Results: Compared with matched controls, case patients were more likely to be exposed to hypnotics 30 days or an average daily defined dose > 0.5 within 90 days before the date of AVF failure, with an adjusted odds ratio of 1.21 (95% confidence interval [CI]: 1.09–1.35, p < 0.001) and 1.36 (95%CI: 1.13–1.63, p = 0.001), respectively. Risk of AVF failure associated with hypnotic use was also observed among HD patients who were male, were younger than 65 years, had hypertension, and did not use statins. Conclusions: Hypnotic use among HD patients was associated with an increased risk of AVF failure.

KW - arteriovenous fistula failure

KW - hemodialysis

KW - hypnotics

KW - nested case–control study

KW - pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=84979986057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979986057&partnerID=8YFLogxK

U2 - 10.1002/pds.3963

DO - 10.1002/pds.3963

M3 - Article

C2 - 26799147

AN - SCOPUS:84979986057

VL - 25

SP - 889

EP - 897

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 8

ER -